NCT01273597 · OUTCOME

Time (in Weeks) From Treatment Initiation to Achieving Maintenance Dose of Zemplar (Paricalcitol Injection)

Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands · Source last updated 2013-01-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: weeks
Interval / dispersion: Standard Deviation
Time frame: 6 months

What was measured

Maintenance dose is defined as weekly dose of paricalcitol that results in at least 2 consecutive intact parathyroid hormone (iPTH) values within the target therapeutic range of 150 - 300 pg/mL, corresponding to 15.9 - 31.8 pmol/L.

Analysis population: Participants who achieved maintenance dose of Zemplar (paricalcitol injection)

Groups in this outcome

End-stage Kidney Disease With Secondary Hyperparathyroidism

Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
End-stage Kidney Disease With Secondary Hyperparathyroidism	16

Reported measurements

Source class 1

Values in weeks · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
End-stage Kidney Disease With Secondary Hyperparathyroidism	12.2	7.6	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
7.6
value
12.2

denoms

counts
group Id
OG000
value
16
units
Participants

description

dispersion Type

Standard Deviation

groups

description
Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)
id
OG000
title
End-stage Kidney Disease With Secondary Hyperparathyroidism

param Type

MEAN

population Description

Participants who achieved maintenance dose of Zemplar (paricalcitol injection)

reporting Status

POSTED

time Frame

6 months

title

Time (in Weeks) From Treatment Initiation to Achieving Maintenance Dose of Zemplar (Paricalcitol Injection)

type

PRIMARY

unit Of Measure

weeks

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice